Skip to content
sellWeak

Barbara Ryan sold $5,426 of INKT

director at MiNK Therapeutics, Inc.. 500 shares at an average of $10.85, traded Feb 27, 2026, filed Mar 4, 2026.

Warning score
15
Value
$5,426
500 shares
Holdings after
21,906
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $5k at market
    0
  • Share of holdings sold
    Sold 2.2% of holdings
    0
  • Cluster
    No other insider selling within 14 days
    0

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -2.0%, 3m +17.0%, 6m +3.9%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

INKTOct 13, 2026 · close 10.23
Since filing Mar 4, 2026: -6.2%SPY +14.4% · excess -20.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-26-091707, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 27, 2026SOpen-market sale
Common Stock
-400$10.86$4,34322,006Mar 4, 2026
Mar 2, 2026SOpen-market sale
Common Stock
-100$10.83$1,08321,906Mar 4, 2026

Related signals

Other insiders at MiNK Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
15Weak
INKTsell
MiNK Therapeutics, Inc.
Barbara Ryan
director
$19k
1,500 shares
-6%
15Weak
INKTsell
MiNK Therapeutics, Inc.
Barbara Ryan
director
$22k
1,500 shares
-7%
15Weak
INKTbuy
MiNK Therapeutics, Inc.
Agenus Inc
owner
$25k
22,975 shares
+0%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Barbara Ryan sold $5,426 of INKT | InsiderTell